Subsequent Events	12 Months Ended
Dec. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events At-the-Market Offering Subsequent to December 31, 2024, from January 1, 2025 through January 6, 2025, the Company raised aggregate net proceeds of $25.1 million under the at-the-market offering pursuant to the January 2024 Sales Agreement with Jefferies as sales agent. As of January 6, 2025, approximately $156.6 million of common stock remained available to be sold under the ATM facility. Commencement of Expansion Premises Office Lease - South San Francisco The Company commenced the First Amendment to the Lease Agreement by and between DW LSP 5000 Shoreline, LLC and the Company in January 2025. The Company added approximately 11,321 rentable square feet of additional space to expand the size of the original premises. Clinical Study Collaboration and Supply Agreement On February 12, 2025, the Company entered into the Second Gilead CSCSA with Gilead pursuant to which the Company and Gilead will collaborate on a portion of the Phase 1 study for the clinical evaluation of IDE397 in combination with Trodelvy, or the Combination Study, in certain patients with advanced solid tumors in lungs. Pursuant to the Second Gilead CSCSA, the Company is the sponsor of the Combination Study, and the Company will provide the IDE397 compound and pay for the costs of the Combination Study.

Subsequent Events

12 Months Ended

Dec. 31, 2024

14. Subsequent Events

At-the-Market Offering

Subsequent to December 31, 2024, from January 1, 2025 through January 6, 2025, the Company raised aggregate net proceeds of $25.1 million under the at-the-market offering pursuant to the January 2024 Sales Agreement with Jefferies as sales agent. As of January 6, 2025, approximately $156.6 million of common stock remained available to be sold under the ATM facility.

Commencement of Expansion Premises Office Lease - South San Francisco

The Company commenced the First Amendment to the Lease Agreement by and between DW LSP 5000 Shoreline, LLC and the Company in January 2025. The Company added approximately 11,321 rentable square feet of additional space to expand the size of the original premises.

Clinical Study Collaboration and Supply Agreement

On February 12, 2025, the Company entered into the Second Gilead CSCSA with Gilead pursuant to which the Company and Gilead will collaborate on a portion of the Phase 1 study for the clinical evaluation of IDE397 in combination with Trodelvy, or the Combination Study, in certain patients with advanced solid tumors in lungs. Pursuant to the Second Gilead CSCSA, the Company is the sponsor of the Combination Study, and the Company will provide the IDE397 compound and pay for the costs of the Combination Study.